Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 1;22:41. doi: 10.1186/s12943-023-01747-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — BC069792 upregulates the expression of KCNQ4 by binding to miR-658 and miR-4739. a Compared with the IgG control group, endogenous BC069792 and KCNQ4-3'UTR were specifically enriched by Ago2 antibody (BC069792: P = 0.017; FOS: P = 0.012; KCNQ4-3'UTR:P < 0.0001). b Through website prediction, database screening and literature query, three miRNAs were identified for further research. c After co-transfection of pmirGLO-BC069792 and mimics in MDA-MB-231 and MDA-MB-468 cell lines, miR-658 (MDA-MB-231: P = 0.021, MDA-MB-468: P = 0.037) and miR-658 -4739 (MDA-MB-231: P = 0.019; MDA-MB-468: P = 0.029) bound to pmirGLO-BC069792 and significantly inhibit luciferase activity. d After co-transfection of pmirGLO-KCNQ4 3'UTR and mimics, both miR-658 (MDA-MB- 231:P = 0.032, MDA-MB- 468:P = 0.017) and miR-4739(MDA-MB-231: P = 0.031; MDA-MB-468:P = 0.046) bound to pmirGLO-KCNQ4 3'UTR and reduced dual-luciferase activity. e There was no significant difference in luciferase activity between the experimental group and the control group after co-transfection of pmirGLO-BC069792-mut (miR-658 binding site mutation) and miR-658 mimics (MDA-MB-231: P = 0.253; MDA-MB-468: P = 0.152). After co-transfection of pmirGLO-BC069792-mut (miR-4739 binding site mutation) and miR-4739 mimics, there was no significant difference in luciferase activity between the experimental group and the control group (MDA-MB-231: P = 0.194; MDA- MB-468: P = 0.084). f There was no significant difference in luciferase activity between the experimental group and the control group after co-transfection of pmirGLO-KCNQ4-3'UTR-mut (miR-658 binding site mutation) and miR-658 mimics (MDA-MB-231: P = 0.160; MDA-MB-468: P = 0.699). After co-transfection of pmirGLO-KCNQ4-3'UTR-mut (miR-4739 binding site mutation) and miR-4739 mimics, there was no significant difference in luciferase activity between the experimental group and the control group (MDA-MB-231:P = 0.210; MDA-MB-468: P = 0.229).g-j In axillary tumors and lung metastases of mice, the expression of miR-658 and miR-4739 in LV-BC069792 group was lower than that in LV-NC group